LABD:NYE-Direxion Daily S&P Biotech Bear 3X Shares (USD)

ETF | Trading--Inverse Equity |

Last Closing

USD 7.08

Change

0.00 (0.00)%

Market Cap

USD 0.08B

Volume

0.04B

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

The fund, under normal circumstances, invests at least 80% of the fund"s net assets in financial instruments, including swap agreements, futures contracts, or short positions, that, in combination, provide 3X daily inverse (opposite) or short exposure to the index or to ETFs that track the index, consistent with the fund"s investment objective. The index is designed to measure the performance of the biotechnology sub-industry based on the GICS. The fund is non-diversified.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-17 )

Largest Industry Peers for Trading--Inverse Equity

ETFs Containing LABD

N/A

Market Performance

  Market Performance vs. Industry/Classification (Trading--Inverse Equity) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -26.93% 45% F 8% B-
Dividend Return 2.20% 26% F 39% F
Total Return -24.74% 45% F 8% B-
Trailing 12 Months  
Capital Gain -62.80% 11% F 2% F
Dividend Return 1.57% 11% F 21% F
Total Return -61.23% 11% F 2% F
Trailing 5 Years  
Capital Gain -97.85% 13% F 1% F
Dividend Return 0.66% 17% F 2% F
Total Return -97.18% 13% F 1% F
Average Annual (5 Year Horizon)  
Capital Gain 186.12% 65% D 98% N/A
Dividend Return 186.96% 65% D 98% N/A
Total Return 0.84% 17% F 21% F
Risk Return Profile  
Volatility (Standard Deviation) 1,300.10% 36% F 2% F
Risk Adjusted Return 14.38% 44% F 31% F
Market Capitalization 0.08B 54% F 25% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.